Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management
February 16 2018 - 7:00AM
Business Wire
CNCR offers diversified exposure to 30 leading
companies with immunotherapy focus
The Loncar Cancer Immunotherapy ETF (Nasdaq: CNCR) recently
surpassed $50 million in assets under management (AUM), marking a
pivotal milestone for the fund.
Launched with a modest seed investment of $2.5 million on Oct.
13, 2015, the ETF has been offering exposure to public companies at
the forefront of cancer immunotherapy research for more than two
years.
Cancer immunotherapy has become an important sector in the
biotechnology space, changing the way many cancers are treated.
CNCR is the first and only ETF to focus exclusively on
immunotherapy and is based on the Loncar Cancer Immunotherapy
Index, an innovative index developed by biotechnology investor and
Loncar Investments CEO Brad Loncar.
“The capital markets play an important role in the development
of new medicines,” Loncar said. “We created this index to highlight
innovative research that has the potential to improve cancer care
and change lives. Important new advances have already reached
patients over this time, and I am optimistic that this is just the
beginning for immunotherapy. I sincerely thank all investors for
your interest.”
In the time since CNCR was launched, FDA approvals for the types
of treatments the fund invests in has vastly expanded, including
new checkpoint inhibitors, an oncolytic virus and landmark
approvals of CAR-T cellular immunotherapies. While the field has
made great strides, there is much more work ahead, as the vast
majority of cancer patients still need better options. Innovative
immunotherapy companies are working hard to build on this progress
and play a disruptive role.
“CNCR was launched with the goal of helping investors gain
exposure to one of the most groundbreaking segments in biotech,”
said J. Garrett Stevens, CEO of Exchange Traded Concepts. “We are
pleased with the reception the fund has received from the
marketplace and grateful to investors for their participation in
it.”
Loncar Investments is an official partner of the Cancer Research
Institute (CRI), the world’s longest running nonprofit organization
dedicated exclusively to harnessing the immune system’s power to
conquer all cancers. To learn about how to give to CRI, please
visit here.
About Exchange Traded Concepts: ETC is carving out a
niche as a portal to launch new, custom exchange-traded funds
efficiently and cost-effectively through a complete turnkey
solution. ETC is a private-label ETF advisor with passive and
active exemptive relief from the Securities and Exchange Commission
(SEC) to launch both domestic and international equity exchange
traded funds under the Investment Company Act of 1940. For more
information, please go to www.exchangetradedconcepts.com.
About Loncar Investments: Loncar Investments, LLC, the
provider of the Loncar Cancer Immunotherapy Index, is committed to
making the biotechnology space more approachable to a wider range
of investors. The company is principally owned by biotech investor
and analyst Brad Loncar. Mr. Loncar manages a biotech-focused
family portfolio from his Lenexa, Kansas office. He can be followed
on Twitter at @bradloncar and his commentary is available at
www.loncarblog.com.
Opinions expressed are those of ETC, Loncar Investments and
their partners and are subject to change, not guaranteed, and
should not be considered investment advice.
Investing involves risk; Principal loss is possible. The Fund
will invest in immunotherapy companies which are highly dependent
on the development, procurement and marketing of drugs and the
protection and exploitation of intellectual property rights. A
company's valuation can also be greatly affected if one of its
products is proven or alleged to be unsafe, ineffective or
unprofitable. The costs associated with developing new drugs can be
significant, and the results are unpredictable. The process for
obtaining regulatory approval by the U.S. Food and Drug
Administration or other governmental regulatory authorities is long
and costly and there can be no assurance that the necessary
approvals with be obtained and maintained. The Fund may invest in
foreign securities, which involve political, economic, currency
risk, greater volatility, and differences in accounting methods.
The Fund is non-diversified meaning it may concentrate its assets
in fewer individual holdings than a diversified fund. Therefore,
the Fund is more exposed to individual stock volatility than a
diversified fund. The Fund invests in smaller companies which may
have more limited liquidity and greater volatility compared to
larger companies. The Fund is not actively managed and may be
affected by a general decline in market segments related to the
index. The fund invests in securities included in, or
representative of securities included in, the index, regardless of
their investment merits. The performance of the fund may diverge
from that of the Index and may experience tracking error to a
greater extent than a fund that seeks to replicate an
index.
The Fund's investment objectives, risks, charges and expenses
must be considered carefully before investing. The summary and
statutory prospectuses contain this and other important information
about the investment company, and may be obtained by calling
800.617.0004 or visiting www.loncarfunds.com. Read it carefully
before investing.
Fund holdings are subject to change and should not be considered
a recommendation to buy or sell any security.
The Loncar Cancer Immunotherapy Index is an index of 30
securities that have a strategic focus on the area of cancer
immunotherapy, or harnessing the immune system to fight cancer.
Quotes for the index can be found under the symbol “LCINDX” on the
Bloomberg Professional service and other financial data
providers.
One may not directly invest in an index.
Diversification does not assure a profit nor protect against
loss in a declining market.
The SEC does not approve or disapprove of any investment.
(www.sec.gov).
Exchange Traded Concepts, LLC serves as the investment advisor
to the Fund. The Loncar Cancer Immunotherapy ETF is distributed by
Quasar Distributors, LLC, which is not affiliated with Exchange
Traded Concepts, LLC or any of its affiliates.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180216005026/en/
Cancer Immunotherapy ETFJill Tatios,
215-240-6398loncar@gregoryfca.com
ETF Series Solutions Tru... (NASDAQ:CNCR)
Historical Stock Chart
From May 2024 to Jun 2024
ETF Series Solutions Tru... (NASDAQ:CNCR)
Historical Stock Chart
From Jun 2023 to Jun 2024